Lipoprotein(a) accelerates atherosclerosis in uremic mice

Journal of Lipid Research

Volumn 51, Issue 10, 2010, Pages 2967-2975

  Pedersen, Tanja X ^a,b   McCormick, Sally P ^c   Tsimikas, Sotirios ^d   Bro, Susanne ^a   Nielsen, Lars B ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherogenesis; Lp(a); OxPL; Uremia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; CREATININE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; TRIACYLGLYCEROL; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; LIPID DIET; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; UREMIA; WILD TYPE;

ANIMALS; ATHEROSCLEROSIS; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MICE; MICE, TRANSGENIC; OXIDATION-REDUCTION; PHOSPHOLIPIDS; UREMIA;

EID: 77956808027     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M006742     Document Type: Article

References (57)

1. Go, A. S., G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu. 2004. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351: 1296-1305.
2. Fellstrom, B. C., A. G. Jardine, R. E. Schmieder, H. Holdaas, K. Bannister, J. Beutler, D. W. Chae, A. Chevaile, S. M. Cobbe, C. Gronhagen-Riska, et al. 2009. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360: 1395-1407.
3. Wanner, C., V. Krane, W. Marz, M. Olschewski, J. F. Mann, G. Ruf, and E. Ritz. 2005. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353: 238-248. (Pubitemid 41058323)
4. Massy, Z. A., O. Ivanovski, T. Nguyen-Khoa, J. Angulo, D. Szumilak, N. Mothu, O. Phan, M. Daudon, B. Lacour, T. B. Drueke, et al. 2005. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J. Am. Soc. Nephrol. 16: 109-116.
5. Bro, S., J. F. Bentzon, E. Falk, C. B. Andersen, K. Olgaard, and L. B. Nielsen. 2003. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J. Am. Soc. Nephrol. 14: 2466-2474.
6. Bro, S., F. Moeller, C. B. Andersen, K. Olgaard, and L. B. Nielsen. 2004. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J. Am. Soc. Nephrol. 15: 1495-1503.
7. Buzello, M., J. Tornig, J. Faulhaber, H. Ehmke, E. Ritz, and K. Amann. 2003. The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J. Am. Soc. Nephrol. 14: 311-316. (Pubitemid 36150854)
8. Bro, S., C. J. Binder, J. L. Witztum, K. Olgaard, and L. B. Nielsen. 2007. Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27: 1080-1086.
9. Bro, S., A. Flyvbjerg, C. J. Binder, C. A. Bang, L. Denner, K. Olgaard, and L. B. Nielsen. 2008. A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis. 201: 274-280.
10. Berliner, J. A., N. Leitinger, and S. Tsimikas. 2009. The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 50(Suppl): S207-S212.
11. Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 102: 1082-1085.
12. Erqou, S., S. Kaptoge, P. L. Perry, A. E. Di, A. Thompson, I. R. White, S. M. Marcovina, R. Collins, S. G. Thompson, and J. Danesh. 2009. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 302: 412-423.
13. Kamstrup, P. R., A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 301: 2331-2339.
14. Nielsen, L. B. 1999. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis. 143: 229-243.
15. Tsimikas, S., and J. L. Witztum. 2008. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr. Opin. Lipidol. 19: 369-377.
16. Schneider, M., J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, et al. 2005. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J. Lipid Res. 46: 769-778.
17. Bergmark, C., A. Dewan, A. Orsoni, E. Merki, E. R. Miller, M. J. Shin, C. J. Binder, S. Horkko, R. M. Krauss, M. J. Chapman, et al. 2008. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49: 2230-2239.
18. Merki, E., M. J. Graham, A. E. Mullick, E. R. Miller, R. M. Crooke, R. E. Pitas, J. L. Witztum, and S. Tsimikas. 2008. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 118: 743-753.
19. Nielsen, L. B., S. Stender, M. Jauhiainen, and B. G. Nordestgaard. 1996. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. J. Clin. Invest. 98: 563-571.
20. Nielsen, L. B., S. Stender, K. Kjeldsen, and B. G. Nordestgaard. 1996. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ. Res. 78: 615-626.
21. Hughes, S. D., X. J. Lou, S. Ighani, J. Verstuyft, D. J. Grainger, R. M. Lawn, and E. M. Rubin. 1997. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J. Clin. Invest. 100: 1493-1500.
22. Mancini, F. P., D. L. Newland, V. Mooser, J. Murata, S. Marcovina, S. G. Young, R. E. Hammer, D. A. Sanan, and H. H. Hobbs. 1995. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler. Thromb. Vasc. Biol. 15: 1911-1916.
23. Fan, J., H. Shimoyamada, H. Sun, S. Marcovina, K. Honda, and T. Watanabe. 2001. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler. Thromb. Vasc. Biol. 21: 88-94. (Pubitemid 32061932)
24. Sun, H., H. Unoki, X. Wang, J. Liang, T. Ichikawa, Y. Arai, M. Shiomi, S. M. Marcovina, T. Watanabe, and J. Fan. 2002. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J. Biol. Chem. 277: 47486-47492.
25. Berg, K., A. Svindland, A. J. Smith, R. M. Lawn, S. Djurovic, A. Alestrom, P. Alestrom, and K. Eliassen. 2002. Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet. Atherosclerosis. 163: 99-104.
26. Parra, H. J., H. Mezdour, C. Cachera, M. Dracon, A. Tacquet, and J. C. Fruchart. 1987. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin. Chem. 33: 721.
27. Yilmaz, F. M., G. Yilmaz, M. Duranay, H. Parpucu, M. Senes, N. Tekeli, and D. Yucel. 2005. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Scand. J. Clin. Lab. Invest. 65: 739-745. (Pubitemid 41759170)
28. Kronenberg, F., G. Utermann, and H. Dieplinger. 1996. Lipoprotein(a) in renal disease. Am. J. Kidney Dis. 27: 1-25.
29. Frischmann, M. E., F. Kronenberg, E. Trenkwalder, J. R. Schaefer, H. Schweer, B. Dieplinger, P. Koenig, K. Ikewaki, and H. Dieplinger. 2007. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 71: 1036-1043.
30. Dieplinger, H., C. Lackner, F. Kronenberg, C. Sandholzer, K. Lhotta, F. Hoppichler, H. Graf, and P. Konig. 1993. Elevated plasma concentrations of lipoprotein(a) in patients with endstage renal disease are not related to the size polymorphism of apolipoprotein(a). J. Clin. Invest. 91: 397-401.
31. Kronenberg, F., P. Konig, U. Neyer, M. Auinger, A. Pribasnig, U. Lang, J. Reitinger, G. Pinter, G. Utermann, and H. Dieplinger. 1995. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 6: 110-120.
32. Sechi, L. A., L. Zingaro, C. Catena, A. Perin, M. S. De, and E. Bartoli. 1999. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int. 56: 1049-1057.
33. Albers, J. J., M. L. Koschinsky, and S. M. Marcovina. 2007. Evidence mounts for a role of the kidney in lipoprotein(a) catabolism. Kidney Int. 71: 961-962.
34. Reblin, T., N. Donarski, L. Fineder, J. H. Brasen, H. Dieplinger, F. Thaiss, R. A. Stahl, U. Beisiegel, and G. Wolf. 2001. Renal handling of human apolipoprotein(a) and its fragments in the rat. Am. J. Kidney Dis. 38: 619-630.
35. Nielsen, L. B., K. Juul, and B. G. Nordestgaard. 1998. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler. Thromb. Vasc. Biol. 18: 641-649.
36. Cain, W. J., J. S. Millar, A. S. Himebauch, U. J. Tietge, C. Maugeais, D. Usher, and D. J. Rader. 2005. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J. Lipid Res. 46: 2681-2691.
37. Ohashi, H., H. Oda, M. Ohno, S. Watanabe, and S. Sakata. 1999. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int. Suppl. 71: S242-S244. (Pubitemid 29304864)
38. Tzanatos, H. A., P. P. Tseke, C. Pipili, K. Retsa, G. Skoutelis, and E. Grapsa. 2009. Cardiovascular risk factors in non-diabetic hemodialysis patients: a comparative study. Ren. Fail. 31: 91-97.
39. Cheesman, E. J., R. J. Sharp, C. H. Zlot, C. Y. Liu, S. Taylor, S. M. Marcovina, S. G. Young, and S. P. McCormick. 2000. An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a). J. Biol. Chem. 275: 28195-28200.
40. Linton, M. F., R. V. Farese, Jr., G. Chiesa, D. S. Grass, P. Chin, R. E. Hammer, H. H. Hobbs, and S. G. Young. 1993. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92: 3029-3037.
41. Callow, M. J., L. J. Stoltzfus, R. M. Lawn, and E. M. Rubin. 1994. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc. Natl. Acad. Sci. USA. 91: 2130-2134.
42. Chiesa, G., H. H. Hobbs, M. L. Koschinsky, R. M. Lawn, S. D. Maika, and R. E. Hammer. 1992. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J. Biol. Chem. 267: 24369-24374.
43. Frazer, K. A., G. Narla, J. L. Zhang, and E. M. Rubin. 1995. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat. Genet. 9: 424-431.
44. Marcovina, S. M., J. J. Albers, B. Gabel, M. L. Koschinsky, and V. P. Gaur. 1995. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin. Chem. 41: 246-255.
45. Pease, R. J., R. W. Milne, W. K. Jessup, A. Law, P. Provost, J. C. Fruchart, R. T. Dean, Y. L. Marcel, and J. Scott. 1990. Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J. Biol. Chem. 265: 553-568.
46. Young, S. G., J. L. Witztum, D. C. Casal, L. K. Curtiss, and S. Bernstein. 1986. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 6: 178-188.
47. Pedersen, T. X., S. Bro, M. H. Andersen, M. Etzerodt, M. Jauhiainen, S. Moestrup, and L. B. Nielsen. 2009. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein E- deficient mice. Atherosclerosis. 202: 372-381.
48. Sanan, D. A., D. L. Newland, R. Tao, S. Marcovina, J. Wang, V. Mooser, R. E. Hammer, and H. H. Hobbs. 1998. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc. Natl. Acad. Sci. USA. 95: 4544-4549.
49. McCormick, S. P., J. K. Ng, S. Taylor, L. M. Flynn, R. E. Hammer, and S. G. Young. 1995. Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc. Natl. Acad. Sci. USA. 92: 10147-10151.
50. Paigen, B. 1995. Genetics of responsiveness to high-fat and high-cholesterol diets in the mouse. Am. J. Clin. Nutr. 62: 458S-462S.
51. Bang, C. A., S. Bro, E. D. Bartels, T. X. Pedersen, and L. B. Nielsen. 2007. Effect of uremia on HDL composition, vascular inflammation, and atherosclerosis in wild-type mice. Am. J. Physiol. Renal Physiol. 293: F1325-F1331.
52. Kronenberg, F., K. Lhotta, P. Konig, R. Margreiter, H. Dieplinger, and G. Utermann. 2003. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. Eur. J. Hum. Genet. 11: 693-699. (Pubitemid 37160991)
53. Himmelfarb, J. 2005. Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol. Clin. 23: 319-330.
54. Ivanovski, O., D. Szumilak, T. Nguyen-Khoa, N. Ruellan, O. Phan, B. Lacour, B. Descamps-Latscha, T. B. Drueke, and Z. A. Massy. 2005. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int. 67: 2288-2294.
55. Scanu, A. M. 2003. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr. Atheroscler. Rep. 5: 106-113.
56. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360: 23-33.
57. Boaz, M., S. Smetana, T. Weinstein, Z. Matas, U. Gafter, A. Iaina, A. Knecht, Y. Weissgarten, D. Brunner, M. Fainaru, et al. 2000. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 356: 1213-1218.